Announcements Trials

Browse Landscape

Sponsor

Conditions

Nasopharyngeal Carcinoma 3 Triple Negative Breast Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Rectal Cancer Patients 1 Pancreatic Neoplasms 1 Locally Advanced Rectal Cancer 1 Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Gemcitabine 29 pembrolizumab 20 Cisplatin 20 Magnetic Resonance Spectroscopy 17 Specimen Handling 16 Mitomycin 10 enfortumab vedotin 9 durvalumab 9 Cystoscopy 9 avelumab 8 Nivolumab 8 Fluorouracil 8 Carboplatin 8 Radiation 7 Cystectomy 6 atezolizumab 5 Transurethral Resection of Bladder 5 Radiotherapy 5 Mitozytrex 5 Docetaxel 5 Biopsy 5 tremelimumab 4 sacituzumab govitecan 4 erdafitinib 4 dehydroftorafur 4 Platinum 4 Immunoglobulin G 4 Disulfides 4 1,2-diaminocyclohexaneplatinum II citrate 4 disitamab vedotin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

0 trials

Recent Start date Enrollment

Urinary Bladder Neoplasms × camrelizumab × 90 days × Clear all

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡